Former President (8) · UroGen Pharma Ltd. (URGN)

Gil Hakim

A named executive officer of UroGen Pharma in every fiscal year CompBrief holds from FY2016 to FY2018. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2018

$3,856,219

Salary $330,791Stock awards $0

FY2017: $1,343,545

3rd of 6 named executive officers at UroGen Pharma by FY2018 total.

6 named officers on file for UroGen Pharma, FY2018

Gil Hakim’s pay file — $29

  • 3 fiscal years of pay, line by line
  • 1 equity grant, each cited to its filing
  • URGN’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how UroGen Pharma’s whole pay program stands against its peers

  • UroGen Pharma’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on URGN→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 26, 2019 (DEF 14A).

Free

Get Gil Hakim’s full pay file as a PDF — free

More than this page: up to 10 years of Gil’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Gil Hakim compensation by year

UroGen Pharma Summary Compensation Table · all 3 fiscal years held
In US dollars, as UroGen Pharma reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2016FY2017FY2018
Salary$207,891$390,406$330,791
Bonus$0$0$0
Stock awards$0$0$0
Option awards$87,847$778,733$1,043,753
Non-equity incentive$84,275$114,242$0
Pension and deferred compensation$0$0$0
All other$40,967$60,164$2,481,675
Total$420,980$1,343,545$3,856,219

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: UroGen Pharma Ltd. DEF 14A filed April 26, 2019, accession 0001193125-19-122589, and prior-year filings. Open the filing on EDGAR.

How this page was built: the UroGen Pharma Ltd. filed document, accession 0001193125-19-122589. Every figure is read from that document and cited to the page and table it appears in. Filed April 26, 2019.

$421K
$1.3M
$3.9M
FY16
FY17
FY18
SalaryNon-equity incentiveOption awardsAll other

UroGen Pharma’s named executive officers, FY2018

as the company reported each
Named executive officerRoleFY2018 total
Ron BentsurFormer Chief Executive Officer (7)$5,950,112
Stephen MullennixChief Operating Officer (9)$4,309,568
Gil Hakim · this pageFormer President (8)$3,856,219
Gary TitusFormer Chief Financial Officer (11)$3,487,109
Peter PfreundschuhChief Financial Officer (8)$2,485,800
Mark SchoenbergChief Medical Officer (10)$300,000

The full UroGen Pharma compensation record

free company brief

This page is one person within UroGen Pharma's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the UroGen Pharma proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are UroGen Pharma's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Gil Hakim's compensation dossier · One-time report. No refunds.